Complement Components, C3 and C4, and the Metabolic Syndrome.


Journal

Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260

Informations de publication

Date de publication:
2019
Historique:
received: 08 08 2017
revised: 10 12 2017
accepted: 13 12 2017
pubmed: 18 4 2018
medline: 13 4 2019
entrez: 18 4 2018
Statut: ppublish

Résumé

Increased systemic inflammation plays a significant role in the development of adult cardiometabolic diseases such as insulin resistance, dyslipidemia, atherosclerosis, and hypertension. The complement system is a part of the innate immune system and plays a key role in the regulation of inflammation. Of particular importance is the activation of complement components C3 and C4. C3 is produced primarily by the liver but is also produced in adipocytes, macrophages and endothelial cells, all of which are present in adipose tissues. Dietary fat and chylomicrons stimulate C3 production. Adipocytes in addition to producing C3 also have receptors for activated C3 and other complement components and thus also respond to as well as produce a target for complement. C3adesArg, also known as acylation stimulation factor, increases adipocyte triglyceride synthesis and release. These physiological effects play a significant role in the development of metabolic syndrome. Epidemiologically, obese adults and non-obese adults with cardiometabolic disease who are not obese have been shown to have increased complement levels. C4 levels also correlate with body mass index. Genetically, specific C3 polymorphisms have been shown to predict future cardiovascular events and. D decreased C4 long gene copy number is associated with increased longevity. Future research is clearly needed to clarify the role of complement in the development of cardiovascular disease and mechanisms for its action. The complement system may provide a new area for intervention in the prevention of cardiometabolic diseases.

Identifiants

pubmed: 29663892
pii: CDR-EPUB-89777
doi: 10.2174/1573399814666180417122030
doi:

Substances chimiques

Complement C3 0
Complement C4 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-48

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR073311
Pays : United States

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Auteurs

Melanie Copenhaver (M)

Pediatric Endocrinology Fellow, Division of Pediatric Endocrinology, Department of Pediatrics, Nationwide Children's Hospital, OH 43205, United States.

Chack-Yung Yu (CY)

Pediatric Endocrinology Fellow, Division of Pediatric Endocrinology, Department of Pediatrics, Nationwide Children's Hospital, OH 43205, United States.

Robert P Hoffman (RP)

Pediatric Endocrinology Fellow, Division of Pediatric Endocrinology, Department of Pediatrics, Nationwide Children's Hospital, OH 43205, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH